GHRP-6 Explained: The Original Secretagogue Hexapeptide, GHS-R1a Pharmacology and Research Uses

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is the first growth hormone-releasing hexapeptide, and its pharmacology is what set researchers on the path to cloning the growth hormone secretagogue receptor GHS-R1a in 1996 and to finding ghrelin, the receptor's natural ligand, in 1999. GHRP-2, hexarelin and ipamorelin are all later refinements of the template GHRP-6 laid down. Among the class it also has the strongest effect on feeding in rodents, which gives it a research niche that extends well beyond endocrinology.

Below we trace the origin of the sequence, explain what its structural elements do, describe the receptor mechanism and published research directions, and cover specification and handling.

Origin and structure: a ligand in search of a receptor

It started with met-enkephalin. During the 1970s and 1980s Cyril Bowers and co-workers were studying analogues of this opioid peptide and found that some fragments triggered growth hormone release. What mattered was what did not happen: GHRH antagonists failed to block the effect, and opioid receptors were not involved. Another target had to exist. GHRP-6 came out of the resulting structure-activity programme as the most practical probe and, for about ten years, was the tool used to search for this unknown receptor. The search paid off twice: GHS-R1a was cloned in 1996, and ghrelin was identified as its endogenous agonist in 1999.

The hexapeptide is organised around two aromatic pairs plus a stabilisation strategy. D-tryptophan at position 2 and D-phenylalanine at position 5 present large aromatic side chains in an orientation that common proteases cannot handle; tryptophan at position 4 adds a second indole; and amidation of the C-terminal lysine removes the terminal negative charge, a feature shared by the whole class. Histidine at position 1 is what later analogues changed, with GHRP-2 using D-alanine instead, because a free N-terminal L-amino acid is an easy target for aminopeptidases.

With a molar mass of 873.01 g/mol, GHRP-6 is the heaviest of the three secretagogues we stock (GHRP-2 is 817.97, ipamorelin 711.85). All three are still far lighter than any GHRH analogue, so 5 mg and 10 mg vials contain a lot of material in molar terms.

Proposed mechanism

GHRP-6 activates GHS-R1a, a class A G protein-coupled receptor found on pituitary somatotrophs, in the arcuate nucleus of the hypothalamus and in peripheral tissues such as the gut. Ligand binding engages Gq, which stimulates phospholipase C to produce inositol trisphosphate and diacylglycerol; the resulting rise in intracellular calcium drives secretory granule release. A reduction in somatostatin tone has also been reported, removing an inhibitory brake just as the stimulatory signal arrives.

Comparative studies highlight two ways in which GHRP-6 differs from later compounds. It is the weakest growth hormone releaser in the series, which is exactly what subsequent medicinal chemistry tried to fix. And its effects are broader: besides growth hormone, published data show rises in prolactin, ACTH and cortisol and, most famously, a strong increase in feeding in rodents, much larger than with GHRP-2 and mostly absent with ipamorelin. This reflects activation of arcuate nucleus circuits, particularly NPY and AgRP neurons, the same route ghrelin uses.

Taken together, GHRP-6 acts less as a selective endocrine probe and more as a broad ghrelin receptor agonist. That is a drawback when the aim is to isolate somatotroph signalling, but for work on ghrelin receptor roles in feeding circuits, gastric motility or cytoprotection it is the right choice and ipamorelin is not. The selectivity trade-off is discussed in ipamorelin vs GHRP-6.

Research directions

Receptor discovery and pharmacology

GHRP-6 is the classic reference agonist for GHS-R1a and is still standard in binding studies, calcium flux and inositol phosphate assays, and in ranking potency across the GHRP family.

Feeding and hypothalamic circuits

Rodent work has measured food intake, activation of arcuate neurons and NPY/AgRP signalling, with GHRP-6 standing in as a synthetic ghrelin mimic. In this line of research it is chosen over the more selective successors, because its lack of selectivity is the very thing being investigated.

Gastric motility and gut models

Because the receptor is also expressed peripherally, ghrelin receptor agonists are studied in models of gastric emptying, gut motility and postoperative ileus.

Cytoprotective and cardiovascular models

A distinct preclinical literature has tested GHRP-6 in tissue-protection and heart models, partly attributing effects to receptors other than GHS-R1a, such as CD36. This work is smaller in scale and less settled.

Combination studies

Combining a secretagogue with a GHRH receptor agonist is a well-established design, because both receptors are present on the same cell but use different second messengers; ready-blended research material is available as CJC-1295 with GHRP-6. Report each molar concentration separately instead of a combined mass, since the two peptides differ in molecular weight about fourfold.

Available formats and sizes

We supply GHRP-6 as lyophilized powder in sealed 5 mg (€50) and 10 mg (€80) vials. At 873.01 g/mol, 5 mg equals roughly 5.73 micromoles, nearly four times the moles in a 5 mg vial of a GHRH analogue. The class is listed under GHRPs and secretagogues, where hexarelin, the most potent compound of the series, is also available.

Reconstitution and storage in the lab

Worked example: 5 mg dissolved in 2 mL of bacteriostatic water gives 2.5 mg/mL (2,500 mcg/mL), so 0.1 mL (10 units on a U-100 syringe) holds 250 mcg. The molar stock concentration is about 2.86 mM; reaching 10 nanomolar in an assay therefore needs roughly a 286,000-fold dilution, carried out stepwise.

Light is the main handling issue for this sequence. It contains two tryptophans, one D-configured, and indole side chains are photosensitive; extended light exposure breaks them down into products that appear as extra chromatographic peaks. Shielding both powder and solution from light is therefore a specific requirement, not a routine courtesy. Otherwise the peptide is chemically robust, with no cysteine, methionine or asparagine. Its three aromatic residues make it less water-friendly than its size implies, so let it dissolve completely and check clarity before use. Store lyophilized vials at −20 °C away from light and moisture, and keep reconstituted solution refrigerated in aliquots. General advice is in the peptide storage guide.

Purity and reading the COA

Each lot is purified by reversed-phase HPLC to at least 99%, with mass confirmation and a lot-specific certificate. Check three things. First, compare the mass with 873.01 g/mol for the C-terminally amidated hexapeptide; about 1 Da more points to the free acid, a pharmacologically different compound. Second, members of the class separate cleanly by mass (873.01 for GHRP-6, 817.97 for GHRP-2, 711.85 for ipamorelin), so a mislabelled vial is obvious on the certificate. Third, read the chromatogram with tryptophan breakdown in mind: early shoulders or small late peaks in a peptide of this makeup deserve scrutiny, as they are typical of light-induced indole degradation. Note too that the D configurations at positions 2 and 5 cannot be confirmed by mass spectrometry, because enantiomers share the same mass. Our COA reading guide explains what each analytical section can and cannot prove.

Regulatory position

GHRP-6 has no marketing authorisation as a medicinal product in the European Union, the United States or elsewhere; it is not a permitted food supplement ingredient and is not a generally available compounded medication. It is supplied for laboratory research only.

Related compounds and further reading

GHRP-2 is the higher-potency successor built on the same framework, hexarelin is the strongest member of the series, and ipamorelin is the selective modern benchmark the older compounds are compared with. On the opposite side of the axis, sermorelin, Modified GRF 1-29 and tesamorelin act at the GHRH receptor via cyclic AMP instead of calcium. The full picture is set out in the GH secretagogue landscape explained.